The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Balancing repair and tolerance of DNA damage caused by alkylating agents
Open accessAbstract
Alkylating agents comprise a major class of frontline chemotherapeutic drugs that inflict cytotoxic DNA damage as their main mode of action, in addition to collateral mutagenic damage. Numerous cellular pathways, including direct DNA damage reversal, base excision repair (BER), and mismatch repair (MMR) respond to alkylation damage to defend against alkylation-induced cell death or mutation. However, maintaining a proper balance of activity both within and between these pathways is crucial for an organism's favorable response to alkylating agents. Furthermore, an individual's response to alkylating agents can vary considerably from tissue to tissue and from person to person, pointing to genetic and epigenetic mechanisms that modulate alkylating agent toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 Kinase
Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., et al. (1995) · Science · doi:10.1126/science.7792600 · Cited by 2,785
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,056
DNA interstrand crosslink repair and cancer
Deans, A. J., & West, S. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3088 · Cited by 1,023
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
Moynahan, M. E., & Jasin, M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2851 · Cited by 930
MUTAGENESIS BY APURINIC/APYRIMIDINIC SITES
Loeb, L. A., & Preston, B. D. (1986) · Annual Review of Genetics · doi:10.1146/annurev.ge.20.120186.001221 · Cited by 901
Research works printed but not linked: 27
- Kufe, D. W. et al. (eds) Cancer Medicine, 6th edn (BC Decker, Hamilton, Canada, 2003).
- Posnick, L. M. & Samson, L. D. Imbalanced base excision repair increases spontaneous mutation and alkylation sensitivity in Escherichia coli. J. Bacteriol. 181, 6763–6771 (1999). · doi:10.1128/jb.181.21.6763-6771.1999
- Calleja, F., Jansen, J. G., Vrieling, H., Laval, F. & van Zeeland, A. A. Modulation of the toxic and mutagenic effects induced by methyl methanesulfonate in Chinese hamster ovary cells by overexpression of the rat N-alkylpurine-DNA glycosylase. Mutat. Res. 425, 185–194 (1999). · doi:10.1016/s0027-5107(99)00034-2
- Freitas, S., Moore, D. H., Michael, H. & Kelley, M. R. Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer. Clin. Cancer Res. 9, 4689–4694 (2003).
- Kakolyris, S. et al. Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). The J. Pathol. 189, 351–357 (1999). · DOI
- Liu, L. & Gerson, S. L. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr. Opin. Investig. Drugs 5, 623–627 (2004).
- Hu, H. Y. et al. Identification of small molecule synthetic inhibitors of DNA polymerase β by NMR chemical shift mapping. J. Biol. Chem. 279, 39736–39744 (2004). · doi:10.1074/jbc.m402842200
- Kelley, M. R. DNA repair inhibitors: where do we go from here? DNA Repair 10, 1183–1185 (2011). · doi:10.1016/j.dnarep.2011.09.003
- Allay, E., Veigl, M. & Gerson, S. L. Mice over-expressing human O6 alkylguanine-DNA alkyltransferase selectively reduce O6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea. Oncogene 18, 3783–3787 (1999). · doi:10.1038/sj.onc.1202697
- Qin, X., Zhou, H., Liu, L. & Gerson, S. L. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis. Carcinogenesis 20, 1667–1673 (1999). · doi:10.1093/carcin/20.9.1667
- Reese, J. S., Qin, X., Ballas, C. B., Sekiguchi, M. & Gerson, S. L. MGMT expression in murine bone marrow is a major determinant of animal survival after alkylating agent exposure. J. Hematother. Stem Cell Res. 10, 115–123 (2001). · doi:10.1089/152581601750098354
- Hongeng, S. et al. O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. Clin. Cancer Res. 3, 2459–2463 (1997).
- Bobola, M. S. et al. O6-methylguanine-DNA methyltransferase in pediatric primary brain tumors. Clin. Cancer Res. 7, 613–619 (2001).
- Weingart, J. et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J. Clin. Oncol. 25, 399–404 (2007). · doi:10.1200/jco.2006.06.6290
- Moritz, T., Mackay, W., Glassner, B. J., Williams, D. A. & Samson, L. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res. 55, 2608–2614 (1995).
- Maze, R. et al. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc. Natl Acad. Sci. USA 93, 206–210 (1996). References 137 and 138 show that transplantation of bone marrow cells overexpressing MGMT can suppress alkylating agent myelosuppression and toxicity in mice. · doi:10.1073/pnas.93.1.206
- Jelinek, J. et al. Long-term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirus-mediated expression of human O6-alkylguanine-DNA-alkyltransferase. Blood 87, 1957–1961 (1996). · doi:10.1182/blood.v87.5.1957.1957
- Allay, J. A., Koç, O. N., Davis, B. M. & Gerson, S. L. Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors. Clin. Cancer Res. 2, 1353–1359 (1996).
- Neff, T. et al. Methylguanine methyltransferase–mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J. Clin. Invest. 112, 1581–1588 (2003). · doi:10.1172/jci200318782
- Maze, R., Hanenberg, H. & Williams, D. A. Establishing chemoresistance in hematopoietic progenitor cells. Mol. Med. Today 3, 350–358 (1997). · doi:10.1016/s1357-4310(97)01094-0
- Jansen, M. et al. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMTP140K into hematopoietic stem cells. Cancer Gene Ther. 9, 737–746 (2002). · doi:10.1038/sj.cgt.7700490
- Lips, J. & Kaina, B. Repair of O6-methylguanine is not affected by thymine base pairing and the presence of MMR proteins. DNA Repair 487, 59–66 (2001). · doi:10.1016/s0921-8777(01)00105-7
- Rasmussen, L. J. & Samson, L. The Escherichia coli MutS DNA mismatch binding protein specifically binds O6-methylguanine DNA lesions. Carcinogenesis 17, 2085–2088 (1996). References 156 and 158 provide a direct link between the MMR pathway and alkylation damage by showing that MUTS and MUTSα can directly recognize O6meG lesions. · doi:10.1093/carcin/17.9.2085
- Kaina, B. The interrelationship between SCE induction, cell survival, mutagenesis, aberration formation and DNA synthesis inhibition in V79 cells treated with N-methyl-N-nitrosourea or N-methyl-N'-nitro-N-nitrosoguanidine. Mutat. Res. 142, 49–54 (1985). · doi:10.1016/s0165-7992(85)80012-9
- Sansom, O. J. & Clarke, A. R. The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice. Oncogene 21, 5934–5939 (2002). · doi:10.1038/sj.onc.1205760
- Sansom, O. J. et al. Apoptosis and mutation in the murine small intestine: loss of Mlh1- and Pms2-dependent apoptosis leads to increased mutation in vivo. DNA Repair 2, 1029–1039 (2003). · doi:10.1016/s1568-7864(03)00111-3
- Bugni, J. M., Meira, L. B. & Samson, L. D. Alkylation-induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins. Oncogene 28, 734–741 (2009). · DOI
Cited by
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
Zhou, Z., Song, J., Nie, L., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00271d · Cited by 2,098
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
DNA damage and the balance between survival and death in cancer biology
Roos, W. P., Thomas, A. D., & Kaina, B. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.2 · Cited by 1,189
The Human Gut Bacterial Genotoxin Colibactin Alkylates DNA
Wilson, M. R., Jiang, Y., Villalta, P. W., Stornetta, A., Boudreau, P. D., Carrá, A., Brennan, C. A., Chun, E., Ngo, L., Samson, L. D., et al. (2019) · Science · doi:10.1126/science.aar7785 · Cited by 635
Self-citationTargeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Inflammation-induced DNA damage, mutations and cancer
Kay, J., Thadhani, E., Samson, L., & Engelward, B. (2019) · DNA Repair · doi:10.1016/j.dnarep.2019.102673 · Cited by 464
Self-citationDNA repair mechanisms in cancer development and therapy
Torgovnick, A., & Schumacher, B. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00157 · Cited by 396
Cardiovascular Complications of Cancer Therapy
Chang, H.-M., Moudgil, R., Scarabelli, T., Okwuosa, T. M., & Yeh, E. T. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1096 · Cited by 385
Interleukin-22 protects intestinal stem cells against genotoxic stress
Gronke, K., Hernández, P. P., Zimmermann, J., Klose, C. S. N., Kofoed-Branzk, M., Guendel, F., Witkowski, M., Tizian, C., Amann, L., Schumacher, F., et al. (2019) · Nature · doi:10.1038/s41586-019-0899-7 · Cited by 373
The experimental power of FR900359 to study Gq-regulated biological processes
Schrage, R., Schmitz, A.-L., Gaffal, E., Annala, S., Kehraus, S., Wenzel, D., Büllesbach, K. M., Bald, T., Inoue, A., Shinjo, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms10156 · Cited by 368
Bacteria in cancer initiation, promotion and progression
El Tekle, G., & Garrett, W. S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00594-2 · Cited by 343
DNA mismatch repair and the DNA damage response
Li, Z., Pearlman, A. H., & Hsieh, P. (2016) · DNA Repair · doi:10.1016/j.dnarep.2015.11.019 · Cited by 307
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all
Oei, A. L., Vriend, L. E. M., Crezee, J., Franken, N. A. P., & Krawczyk, P. M. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0462-0 · Cited by 294
Tang, H. L., Tang, H. M., Mak, K. H., Hu, S., Wang, S. S., Wong, K. M., Wong, C. S. T., Wu, H. Y., Law, H. T., Liu, K., et al. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-11-0926 · Cited by 293
Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B. D., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 292
The Influence of Cell Cycle Regulation on Chemotherapy
Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136923 · Cited by 290
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines · doi:10.3390/biomedicines7030069 · Cited by 279
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential
Huang, W., Chen, T.-Q., Fang, K., Zeng, Z.-C., Ye, H., & Chen, Y.-Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01129-8 · Cited by 275
Knizhnik, A. V., Roos, W. P., Nikolova, T., Quiros, S., Tomaszowski, K.-H., Christmann, M., & Kaina, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055665 · Cited by 273
PARP-1 and its associated nucleases in DNA damage response
Wang, Y., Luo, W., & Wang, Y. (2019) · DNA Repair · doi:10.1016/j.dnarep.2019.102651 · Cited by 272
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 269
Messaoudi, K., Clavreul, A., & Lagarce, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.011 · Cited by 238
ARTD1/PARP1 Negatively Regulates Glycolysis by Inhibiting Hexokinase 1 Independent of NAD+ Depletion
Fouquerel, E., Goellner, E. M., Yu, Z., Gagné, J.-P., Barbi de Moura, M., Feinstein, T., Wheeler, D., Redpath, P., Li, J., Romero, G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.036 · Cited by 212
Inflammation-Induced Cell Proliferation Potentiates DNA Damage-Induced Mutations In Vivo
Kiraly, O., Gong, G., Olipitz, W., Muthupalani, S., & Engelward, B. P. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1004901 · Cited by 169
“Ironically, alkylating agents are used to treat cancer when given at high doses [55].”
BackgroundDNA Repair by Reversal of DNA Damage
Yi, C., & He, C. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012575 · Cited by 161
Yoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Nakamizo, A., & Sasaki, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00186 · Cited by 126
A ubiquitin-dependent signalling axis specific for ALKBH-mediated DNA dealkylation repair
Brickner, J. R., Soll, J. M., Lombardi, P. M., Vågbø, C. B., Mudge, M. C., Oyeniran, C., Rabe, R., Jackson, J., Sullender, M. E., Blazosky, E., et al. (2017) · Nature · doi:10.1038/nature24484 · Cited by 112
Targeting DNA Replication Stress for Cancer Therapy
Zhang, J., Dai, Q., Park, D., & Deng, X. (2016) · Genes · doi:10.3390/genes7080051 · Cited by 102
“, cisplatin and carboplatin) can modify DNA to produce intra‐ and inter‐strand crosslinks between nucleotide bases [20,21].”
BackgroundMaertens, O., Kuzmickas, R., Manchester, H. E., Emerson, C. E., Gavin, A. G., Guild, C. J., Wong, T. C., De Raedt, T., Bowman-Colin, C., Hatchi, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0879 · Cited by 95
“MGMT directly reverses the mutagenic DNA lesion O6-methylguanine, which is caused by alkylating agents (24).”
BackgroundNext-generation DNA damage sequencing
Mingard, C., Wu, J., McKeague, M., & Sturla, S. J. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00647e · Cited by 92
Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments
Wu, X., Qin, L., Fako, V., & Zhang, J.-T. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2013.09.004 · Cited by 82
Aberrant RNA methylation triggers recruitment of an alkylation repair complex
Tsao, N., Brickner, J. R., Rodell, R., Ganguly, A., Wood, M., Oyeniran, C., Ahmad, T., Sun, H., Bacolla, A., Zhang, L., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.024 · Cited by 46
Non-bulky Lesions in Human DNA: The Ways of Formation, Repair, and Replication
Ignatov, А. V., Bondarenko, K. A., & Makarova, A. V. (2017) · Acta Naturae · doi:10.32607/20758251-2017-9-3-12-26 · Cited by 31
Nucleosomes regulate base excision repair in chromatin
Meas, R., Wyrick, J. J., & Smerdon, M. J. (2019) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.10.002 · Cited by 28
Bordin, D. L., Grooms, K., Montaldo, N. P., Fordyce Martin, S. L., Sætrom, P., Samson, L. D., Bjørås, M., & van Loon, B. (2024) · DNA Repair · doi:10.1016/j.dnarep.2024.103632 · Cited by 3
Self-citationA single viral enzyme drives tRNA-dependent hypermodification of DNA at adenine
Silva, R. M. B., Slyvka, A., Lee, Y.-J., Guan, C., Lund, S. R., Raleigh, E. A., Skowronek, K., Kuska, M. S., Bochtler, M., & Weigele, P. R. (2026) · Nature Communications · doi:10.1038/s41467-026-70671-1 · Cited by 3
Metadata
- Authors
- Fu, D., Calvo, J. A., & Samson, L. D.
- Venue
- Nature Reviews Cancer
- Published
- 2012-01-12
- Volume
- 12
- Issue
- 2
- Pages
- 104-120
- ISSN
- 1474-175X
- 1474-1768
- OpenAlex
- W2094144162
- Cited by
- 947
- References
- 185
- FWCI
- 21.03
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.